Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Chucky99 who wrote (1885)	5/16/1999 6:47:00 PM
From: DaveAu	Read Replies (1) \| Respond to of 14101

Hey Chucky Do you come from a Galaxo far far away ? BJ

To: Chucky99 who wrote (1885)	5/16/1999 8:33:00 PM
From: CJG	Respond to of 14101

Welcome to the thread Chucky99. As Bluejay has indicated, this thread is full of well versed individuals (excluding me) in this field. You being new to the stock, I suggest you take the time in reading through the thread, like I have done over the past year. Most certainly visit the company's website. As to the Galaxo (Oops Glaxo) deal, all I can say is I can wait for the company to official announce their selected partner. Rumour are rumours until announced by the powers to be. I would be interested in you giving the thread the numbers to support the price as you suggested. There has been other numbers posted on this thread before. Regards CJG

To: Chucky99 who wrote (1885)	5/16/1999 10:16:00 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

hi Chucky99, I have no problem with the distribution partner being Glaxo. You mentioned numbers though, and I like numbers. When you say $20, do you mean right after the announcement of the deal and FDA approval? I think that may be a bit high unless they change the name 'Pennsaid' quickly to 'E-Commerce' and then announce the approval. Just kidding. Welcome to the thread. Nice timing. Let me share some of my numbers with you (a new victim), To achieve a true breakeven ($0 eps), the manufacturing facilities need to produce 2,500 tubes of Pennsaid a day based on 260 days and a gross margin (after all direct costs) of $20 a tube. The price currently is $60 for a month (I assume that's one tube) and I'm assuming Dimethaid sells to the distributor at $30. I'm probably low on manufacturing costs and low on the split (Dimethaid does a little better). This is based on them manufacturing and selling to the big X who then picks up marketing and distribution costs. Not a big ad campaign budget out of that - but then thats only assuming Pennsaid gets 55,000 of the 5,500,000 patient market and this is only for purposes of earnings per share breakeven analysis. Europe of course is a separate story. So basically 1% market penetration is good enough for eps breakeven as long as they can pump out 2,500 of those little darlings a day. I have an e-mail into Peter on capacity and expansion capabilities. Obviously I'm looking for a considerably higher number. Just to bore you to death, I'm really looking forward to this long weekend. I'm getting away early on Friday and this time I've packed something early for the weekend. A calculator.